Chronic cutaneous graft-versus-host disease in children: A report of 14 patients from a tertiary care pediatric dermatology clinic

Affiliations

01 May 2018

-

doi: 10.1111/pde.13432


Abstract

Background/objectives: Allogeneic hematopoietic stem cell transplantation (HSCT) is a treatment option for many life-threatening disorders in children. Chronic graft-versus-host disease (cGVHD) is a significant complication of HSCT, and its treatment is challenging. Skin is the most common organ affected in cGVHD, with protean manifestations posing a challenge in diagnosis and management. The objective was to have a better understanding of the spectrum of chronic cutaneous GVHD (cc-GVHD) in children.

Methods: Hospital records of 14 children with cc-GVHD, registered over 9 years, were reviewed.

Results: All the patients had received HSCT from related donors. Median duration between HSCT and onset of cc-GVHD was 7.5 months. Eighty-six percent of the patients had a prior history of aGVHD, and 14% had de novo onset of cc-GVHD. Of 14 patients, 71% had classic cc-GVHD. Overlap syndrome was observed in 29%. Tandem occurrence of multiple morphologies was noticed in 6 (43%) patients. Of classic cc-GVHD, lichen planus-like cc-GVHD was most common (57%) followed by scleroderma-like (29%) and poikiloderma (7%). Rare variants included eczema-like (14%) and psoriasis-like (7%) cc-GVHD. Mucosal involvement was seen in 78.6% of the patients, nail involvement in 50%, and hair abnormalities in 43%. After a median follow-up of 4.8 years, complete remission was observed in 50% and mortality in 14%.

Conclusion: The study signifies the diverse nature of cc-GVHD and indicates the need for multicenter surveys including larger number of patients to have proper insight into and develop treatment guidelines for cc-GVHD in children.

Keywords: allogeneic; chronic cutaneous graft versus host disease; chronic graft versus host disease; graft versus host disease; hematopoietic stem cell transfer; skin manifestations.


Similar articles

Cutaneous Chronic Graft Versus Host Disease Following Allogeneic Haematopoietic Stem Cell Transplantation in Children: A Retrospective Study.

Shreberk-Hassidim R, Neumark M, Greenberger S, Goldstein G, Hassidim A, Dukler Y, Maly A, Stepensky P, Molho-Pessach V.Acta Derm Venereol. 2018 Feb 7;98(2):206-211. doi: 10.2340/00015555-2824.PMID: 29057425

Pediatric Cutaneous Graft Versus Host Disease: A Review.

Shi CR, Huang JT, Nambudiri VE.Curr Pediatr Rev. 2017;13(2):100-110. doi: 10.2174/1573396313666170615091733.PMID: 28641548 Review.

Partial reconstitution of cutaneous microvessels in long-term survivors after allogeneic bone marrow transplantation.

Haeusermann P, Kump E, Rovó A, Tichelli A, Itin P, Gratwohl A, Biedermann BC.Dermatology. 2009;219(1):32-41. doi: 10.1159/000216934. Epub 2009 Apr 29.PMID: 19407437

Chronic graft-versus-host disease of the kidney in patients with allogenic hematopoietic stem cell transplant.

Fraile P, Vazquez L, Caballero D, Garcia-Cosmes P, López L, San Miguel J, Tabernero JM.Eur J Haematol. 2013 Aug;91(2):129-34. doi: 10.1111/ejh.12149. Epub 2013 Jun 28.PMID: 23710658

Cutaneous manifestations of graft-versus-host disease: role of the dermatologist.

Kavand S, Lehman JS, Hashmi S, Gibson LE, El-Azhary RA.Int J Dermatol. 2017 Feb;56(2):131-140. doi: 10.1111/ijd.13381. Epub 2016 Sep 23.PMID: 27658806 Review.


Cited by

Epidermal barrier function in patients after allogeneic hematopoietic stem cell transplantation - a pilot study.

Polańska A, Łojko-Dankowska A, Czyż A, Adamski Z, Żaba R, Gil L, Dańczak-Pazdrowska A.Postepy Dermatol Alergol. 2022 Dec;39(6):1083-1087. doi: 10.5114/ada.2022.116778. Epub 2022 Jun 7.PMID: 36686018 Free PMC article.

Rehabilitation in Children With Sclerodermoid Chronic Graft-Versus-Host Disease: Case Series.

Jung M, Sung IY, Ko EJ.Ann Rehabil Med. 2019 Jun;43(3):347-351. doi: 10.5535/arm.2019.43.3.347. Epub 2019 Jun 28.PMID: 31311258 Free PMC article.


KMEL References